BRIEF-Arch Biopartners says European Commission designated AB569 as orphan medicinal product in EU
June 01, 2016 at 15:31 PM EDT
* European Commission designated AB569 as orphan medicinal product in European Union for treatment of patients with cystic fibrosis Source text for Eikon: Further company coverage:
